

Kick Off Symposium by Distinguished Oncologists at Kobe University in Promotion Plan for the Platform of Human Resource Development for Cancer

神戸大学がんプロフェッショナル養成基盤推進プラン Kick Off シンポジウム

Date : July 30, 2012

Time : 18:00-20:15

Place : Sysmex Hall

Kobe University Graduate School of Medicine

* This Symposium is in English and Open Door.
(入場自由・申込不要)

神戸大学大学院医学研究科

共催 : 株式会社ヤクルト本社, ファイザー株式会社
地域がん診療拠点病院神戸大学医学部附属病院

日時 : 2012年7月30日(月)18時00分

場所 : 神戸大学医学部 シスメックスホール

Div. of Medical Oncology/Hematology 腫瘍・血液内科学分野

Prof. Hironobu Minami 教授 南 博信

Tel 078-382-5820 Ex. 5820 hminami@med.kobe-u.ac.jp

or Research Support Div. 研究支援課 古池 Koike
EX. 5213 maico@med.kobe-u.ac.jp

■ Program :

1. 開催のご挨拶 (南 博信 : がんプロフェッショナル養成基盤推進プラン・リーダー) 18:00-18:05
2. 講演1 : *Current and Emerging Therapeutic Targets in Non-Small Cell Lung Cancer* 18:05-19:05
Dr. Pasi Jänne, M.D., Ph.D. *Chairperson: Toru Mukohara*
(質疑応答)
- 講演2 : *The Neoadjuvant Approach to Treat and Study Early Breast Cancer in the Era of Molecular Target Drugs* 19:10-20:10
Dr. Luca Gianni, M.D., Ph.D. *Chairperson: Hironobu Minami*
(質疑応答)
3. 総括 (南 博信) 20:10-20:15

Pasi Jänne, M.D., won 2010 American Association of Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award.

Dr. Jänne is an Associate Professor of Medicine at Harvard Medical School and the co-director of the Belfer Institute for Applied Cancer Sciences. He is also a co-leader of the DF/HCC lung cancer program.

Dr Jänne's research combines laboratory-based translational research and clinical trials of novel therapeutic agents in patients with lung cancer. In 2004, he was the co-first author of studies that identified somatic mutations in EGFR in NSCLC and demonstrated their association with the efficacy of the EGFR kinase inhibitors. His current research interests focus on understanding mechanisms of acquired resistance to targeted therapies and developing therapeutic strategies for drug resistant cancers.

He has received several awards for his research including from Uniting Against Lung Cancer, American Lung Association and the Bonnie J. Addario Lung Cancer Foundation. In 2008 he was elected as a member to the American Society of Clinical Investigation. He is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.

Dr. Pasi Jänne, M.D., Ph.D.

Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, U.S.A.

Luca Gianni, M.D., is the winner of the 2011 Gianni Bonadonna Breast Cancer Award from the American Society of Clinical Oncology (ASCO).

Luca Gianni, M.D. is Director of the Department of Medical Oncology and Head of the Strategic Project of New Drug Development in Solid Tumors at the Ospedale San Raffaele in Milan, Italy. For many years he has worked on new drug development in the field of oncology, and on the pharmacological characterization and clinical application of innovative drug therapies in medical oncology, with special emphasis on breast cancer.

Since 1996, he has been the coordinator of a European Cooperative Group conducting trials in women with operable breast cancer. He is also Advisor and Expert for Research Applications to the Italian Ministry of University and Research. In 1997 he founded the Michelangelo Foundation for the Advancement of Science and Treatment in Oncology, and is Chairman of the International Board of the Michelangelo Foundation Breast Cancer Study Group.

Dr. Luca Gianni, M.D., Ph.D.

Director, Department of Medical Oncology, Ospedale San Raffaele, Milano, Italy

